ID   LCK_HUMAN               Reviewed;         509 AA.
AC   P06239; P07100; Q12850; Q13152; Q5TDH8; Q5TDH9; Q7RTZ3; Q96DW4;
AC   Q9NYT8;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 6.
DT   05-OCT-2010, entry version 158.
DE   RecName: Full=Tyrosine-protein kinase Lck;
DE            EC=2.7.10.2;
DE   AltName: Full=Leukocyte C-terminal Src kinase;
DE            Short=LSK;
DE   AltName: Full=Lymphocyte cell-specific protein-tyrosine kinase;
DE   AltName: Full=Protein YT16;
DE   AltName: Full=Proto-oncogene Lck;
DE   AltName: Full=T cell-specific protein-tyrosine kinase;
DE   AltName: Full=p56-LCK;
GN   Name=LCK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=87133831; PubMed=3493153; DOI=10.1002/eji.1830161229;
RA   Koga Y., Caccia N., Toyonaga B., Spolski R., Yanagi Y., Yoshikai Y.,
RA   Mak T.W.;
RT   "A human T cell-specific cDNA clone (YT16) encodes a protein with
RT   extensive homology to a family of protein-tyrosine kinases.";
RL   Eur. J. Immunol. 16:1643-1646(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=89123626; PubMed=3265417; DOI=10.1002/jcb.240380206;
RA   Perlmutter R.M., Marth J.D., Lewis D.B., Peet R., Ziegler S.F.,
RA   Wilson C.B.;
RT   "Structure and expression of lck transcripts in human lymphoid
RT   cells.";
RL   J. Cell. Biochem. 38:117-126(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=90108697; PubMed=2558056; DOI=10.1016/0378-1119(89)90144-3;
RA   Rouer E., van Huynh T., de Souza S.L., Lang M.C., Fischer S.,
RA   Benarous R.;
RT   "Structure of the human lck gene: differences in genomic organisation
RT   within src-related genes affect only N-terminal exons.";
RL   Gene 84:105-113(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], VARIANTS LEU-28; GLN-LYS-PRO-232 INS;
RP   VAL-353 AND LEU-447, AND PHOSPHORYLATION AT TYR-394 AND TYR-505.
RC   TISSUE=Leukemia;
RX   MEDLINE=94187714; PubMed=8139546;
RA   Wright D.D., Sefton B.M., Kamps M.P.;
RT   "Oncogenic activation of the Lck protein accompanies translocation of
RT   the LCK gene in the human HSB2 T-cell leukemia.";
RL   Mol. Cell. Biol. 14:2429-2437(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), AND ALTERNATIVE SPLICING.
RC   TISSUE=Leukemic T-cell;
RX   MEDLINE=96085119; PubMed=7495859; DOI=10.1016/0167-4781(95)00162-A;
RA   Vogel L.B., Arthur R., Fujita D.J.;
RT   "An aberrant lck mRNA in two human T-cell lines.";
RL   Biochim. Biophys. Acta 1264:168-172(1995).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=22289034; PubMed=12401726;
RA   Nervi S., Nicodeme S., Gartioux C., Atlan C., Lathrop M., Reviron D.,
RA   Naquet P., Matsuda F., Imbert J., Vialettes B.;
RT   "No association between lck gene polymorphisms and protein level in
RT   type 1 diabetes.";
RL   Diabetes 51:3326-3330(2002).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-35.
RX   MEDLINE=89096891; PubMed=2850479;
RA   Garvin A.M., Pawar S., Marth J.D., Perlmutter R.M.;
RT   "Structure of the murine lck gene and its rearrangement in a murine
RT   lymphoma cell line.";
RL   Mol. Cell. Biol. 8:3058-3064(1988).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-35.
RX   MEDLINE=89313764; PubMed=2787474;
RA   Takadera T., Leung S., Gernone A., Koga Y., Takihara Y.,
RA   Miyamoto N.G., Mak T.W.;
RT   "Structure of the two promoters of the human lck gene: differential
RT   accumulation of two classes of lck transcripts in T cells.";
RL   Mol. Cell. Biol. 9:2173-2180(1989).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 14-509.
RC   TISSUE=Peripheral blood lymphocyte;
RX   MEDLINE=20462621; PubMed=11009097;
RX   DOI=10.1002/1521-4141(200009)30:9<2632::AID-IMMU2632>3.0.CO;2-C;
RA   Boncristiano M., Majolini M.B., D'Elios M.M., Pacini S., Valensin S.,
RA   Ulivieri C., Amedei A., Falini B., Del Prete G., Telford J.L.,
RA   Baldari C.T.;
RT   "Defective recruitment and activation of ZAP-70 in common variable
RT   immunodeficiency patients with T cell defects.";
RL   Eur. J. Immunol. 30:2632-2638(2000).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 368-509.
RX   MEDLINE=88217332; PubMed=2835736;
RA   Veillette A., Foss F.M., Sausville E.A., Bolen J.B., Rosen N.;
RT   "Expression of the lck tyrosine kinase gene in human colon carcinoma
RT   and other non-lymphoid human tumor cell lines.";
RL   Oncogene Res. 1:357-374(1987).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 375-509.
RX   MEDLINE=87000726; PubMed=3489486; DOI=10.1016/0167-4889(86)90228-4;
RA   Trevillyan J.M., Lin Y., Chen S.J., Phillips C.A., Canna C.,
RA   Linna T.J.;
RT   "Human T lymphocytes express a protein-tyrosine kinase homologous to
RT   p56LSTRA.";
RL   Biochim. Biophys. Acta 888:286-295(1986).
RN   [15]
RP   PHOSPHORYLATION AT TYR-505.
RX   MEDLINE=92347326; PubMed=1639064;
RA   Bergman M., Mustelin T., Oetken C., Partanen J., Flint N.A.,
RA   Amrein K.E., Autero M., Burn P., Alitalo K.;
RT   "The human p50csk tyrosine kinase phosphorylates p56lck at Tyr-505 and
RT   down regulates its catalytic activity.";
RL   EMBO J. 11:2919-2924(1992).
RN   [16]
RP   INTERACTION WITH PI3K.
RX   MEDLINE=94067101; PubMed=7504174;
RA   Vogel L.B., Fujita D.J.;
RT   "The SH3 domain of p56lck is involved in binding to
RT   phosphatidylinositol 3'-kinase from T lymphocytes.";
RL   Mol. Cell. Biol. 13:7408-7417(1993).
RN   [17]
RP   INTERACTION WITH KHDRBS1.
RX   MEDLINE=95155308; PubMed=7852312; DOI=10.1074/jbc.270.6.2506;
RA   Vogel L.B., Fujita D.J.;
RT   "p70 phosphorylation and binding to p56lck is an early event in
RT   interleukin-2-induced onset of cell cycle progression in T-
RT   lymphocytes.";
RL   J. Biol. Chem. 270:2506-2511(1995).
RN   [18]
RP   INTERACTION WITH SQSTM1, AND MUTAGENESIS OF SER-59 AND ARG-154.
RX   PubMed=8618896; DOI=10.1073/pnas.92.26.12338;
RA   Park I., Chung J., Walsh C.T., Yun Y., Strominger J.L., Shin J.;
RT   "Phosphotyrosine-independent binding of a 62-kDa protein to the src
RT   homology 2 (SH2) domain of p56lck and its regulation by
RT   phosphorylation of Ser-59 in the lck unique N-terminal region.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:12338-12342(1995).
RN   [19]
RP   INTERACTION WITH HIV-1 NEF.
RX   MEDLINE=96386556; PubMed=8794306;
RA   Greenway A.L., Azad A., Mills J., McPhee D.A.;
RT   "Human immunodeficiency virus type 1 Nef binds directly to LCK and
RT   mitogen-activated protein kinase, inhibiting kinase activity.";
RL   J. Virol. 70:6701-6708(1996).
RN   [20]
RP   REVIEW.
RX   PubMed=10848956; DOI=10.1046/j.1432-1327.2000.01412.x;
RA   Isakov N., Biesinger B.;
RT   "Lck protein tyrosine kinase is a key regulator of T-cell activation
RT   and a target for signal intervention by Herpesvirus saimiri and other
RT   viral gene products.";
RL   Eur. J. Biochem. 267:3413-3421(2000).
RN   [21]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12218089;
RA   Yasuda K., Nagafuku M., Shima T., Okada M., Yagi T., Yamada T.,
RA   Minaki Y., Kato A., Tani-Ichi S., Hamaoka T., Kosugi A.;
RT   "Fyn is essential for tyrosine phosphorylation of Csk-binding
RT   protein/phosphoprotein associated with glycolipid-enriched
RT   microdomains in lipid rafts in resting T cells.";
RL   J. Immunol. 169:2813-2817(2002).
RN   [22]
RP   MASS SPECTROMETRY.
RC   TISSUE=Mammary cancer;
RX   MEDLINE=21829512; PubMed=11840567;
RX   DOI=10.1002/1615-9861(200202)2:2<212::AID-PROT212>3.0.CO;2-H;
RA   Harris R.A., Yang A., Stein R.C., Lucy K., Brusten L., Herath A.,
RA   Parekh R., Waterfield M.D., O'Hare M.J., Neville M.A., Page M.J.,
RA   Zvelebil M.J.;
RT   "Cluster analysis of an extensive human breast cancer cell line
RT   protein expression map database.";
RL   Proteomics 2:212-223(2002).
RN   [23]
RP   INTERACTION WITH LIME1.
RX   PubMed=14610046; DOI=10.1084/jem.20031484;
RA   Brdickova N., Brdicka T., Angelisova P., Horvath O., Spicka J.,
RA   Hilgert I., Paces J., Simeoni L., Kliche S., Merten C., Schraven B.,
RA   Horejsi V.;
RT   "LIME: a new membrane raft-associated adaptor protein involved in CD4
RT   and CD8 coreceptor signaling.";
RL   J. Exp. Med. 198:1453-1462(2003).
RN   [24]
RP   INTERACTION WITH LIME1.
RX   PubMed=14610044; DOI=10.1084/jem.20030232;
RA   Hur E.M., Son M., Lee O.-H., Choi Y.B., Park C., Lee H., Yun Y.;
RT   "LIME, a novel transmembrane adaptor protein, associates with p56lck
RT   and mediates T cell activation.";
RL   J. Exp. Med. 198:1463-1473(2003).
RN   [25]
RP   INTERACTION WITH PTPRH.
RX   PubMed=12837766; DOI=10.1074/jbc.M300648200;
RA   Ito T., Okazawa H., Maruyama K., Tomizawa K., Motegi S., Ohnishi H.,
RA   Kuwano H., Kosugi A., Matozaki T.;
RT   "Interaction of SAP-1, a transmembrane-type protein-tyrosine
RT   phosphatase, with the tyrosine kinase Lck. Roles in regulation of T
RT   cell function.";
RL   J. Biol. Chem. 278:34854-34863(2003).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-394 AND TYR-505, AND
RP   MASS SPECTROMETRY.
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-192 AND TYR-505, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-162; TYR-192; SER-213;
RP   TYR-394; THR-501 AND TYR-505, AND MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=17192257; DOI=10.1074/mcp.T600062-MCP200;
RA   Wissing J., Jaensch L., Nimtz M., Dieterich G., Hornberger R.,
RA   Keri G., Wehland J., Daub H.;
RT   "Proteomics analysis of protein kinases by target class-selective
RT   prefractionation and tandem mass spectrometry.";
RL   Mol. Cell. Proteomics 6:537-547(2007).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-505, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-505, AND MASS
RP   SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-102; THR-159; SER-162;
RP   TYR-192; SER-194 AND TYR-505, AND MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [32]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-179, AND MASS SPECTROMETRY.
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 53-226.
RX   MEDLINE=94203291; PubMed=7512222; DOI=10.1038/368764a0;
RA   Eck M.J., Atweell S.K., Shoelson S.E., Harrison S.C.;
RT   "Structure of the regulatory domains of the Src-family tyrosine kinase
RT   Lck.";
RL   Nature 368:764-769(1994).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 127-221.
RX   MEDLINE=95173978; PubMed=7532720; DOI=10.1006/jmbi.1994.0089;
RA   Mikol V., Baumann G., Keller T.H., Manning U.M., Zurini M.G.M.;
RT   "The crystal structures of the SH2 domain of p56lck complexed with two
RT   phosphonopeptides suggest a gated peptide binding site.";
RL   J. Mol. Biol. 246:344-355(1995).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (1.0 ANGSTROMS) OF 122-226.
RX   MEDLINE=96177765; PubMed=8604142; DOI=10.1006/jmbi.1996.0112;
RA   Tong L., Warren T.C., King J., Betageri R., Rose J., Jakes S.;
RT   "Crystal structures of the human p56lck SH2 domain in complex with two
RT   short phosphotyrosyl peptides at 1.0-A and 1.8-A resolution.";
RL   J. Mol. Biol. 256:601-610(1996).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 231-501.
RX   MEDLINE=97100952; PubMed=8945479; DOI=10.1038/384484a0;
RA   Yamaguchi H., Hendrickson W.A.;
RT   "Structural basis for activation of human lymphocyte kinase Lck upon
RT   tyrosine phosphorylation.";
RL   Nature 384:484-489(1996).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 119-226.
RX   MEDLINE=98352059; PubMed=9685372; DOI=10.1074/jbc.273.32.20238;
RA   Tong L., Warren T.C., Lukas S., Schembri-King J., Betageri R.,
RA   Proudfoot J.R., Jakes S.;
RT   "Carboxymethyl-phenylalanine as a replacement for phosphotyrosine in
RT   SH2 domain binding.";
RL   J. Biol. Chem. 273:20238-20242(1998).
CC   -!- FUNCTION: Tyrosine kinase that plays an essential role for the
CC       selection and maturation of developing T-cell in the thymus and in
CC       mature T-cell function. Is constitutively associated with the
CC       cytoplasmic portions of the CD4 and CD8 surface receptors and
CC       plays a key role in T-cell antigen receptor(TCR)-linked signal
CC       transduction pathways. Association of the TCR with a peptide
CC       antigen-bound MHC complex facilitates the interaction of CD4 and
CC       CD8 with MHC class II and class I molecules, respectively, and
CC       thereby recruits the associated LCK to the vicinity of the TCR/CD3
CC       complex. LCK then phosphorylates tyrosines residues within the
CC       immunoreceptor tyrosines-based activation motifs (ITAMs) in the
CC       cytoplasmic tails of the TCRgamma chains and CD3 subunits,
CC       initiating the TCR/CD3 signaling pathway. In addition, contributes
CC       to signaling by other receptor molecules. Associates directly with
CC       the cytoplasmic tail of CD2, and upon engagement of the CD2
CC       molecule, LCK undergoes hyperphosphorylation and activation. Also
CC       plays a role in the IL2 receptor-linked signaling pathway that
CC       controls T-cell proliferative response. Binding of IL2 to its
CC       receptor results in increased activity of LCK. Is expressed at all
CC       stages of thymocyte development and is required for the regulation
CC       of maturation events that are governed by both pre-TCR and mature
CC       alpha beta TCR.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- ENZYME REGULATION: Inhibited by tyrosine phosphorylation.
CC   -!- SUBUNIT: Binds to the cytoplasmic domain of cell surface
CC       receptors, such as CD2, CD4, CD5, CD8, CD44, CD45 and CD122. Also
CC       binds to effector molecules, such as PI4K, VAV1, RASA1, FYB and to
CC       other protein kinases including CDK1, RAF1, ZAP70 and SYK. Binds
CC       to phosphatidylinositol 3'-kinase (PI3K) from T-lymphocytes
CC       through its SH3 domain and to the tyrosine phosphorylated form of
CC       KHDRBS1/p70 through its SH2 domain. Binds to HIV-1 Nef through its
CC       SH3 domain. This interaction inhibits its tyrosine-kinase
CC       activity. Interacts with SQSTM1. Interacts with phosphorylated
CC       LIME1. Interacts with CBLB and PTPRH.
CC   -!- INTERACTION:
CC       P27958:- (xeno); NbExp=1; IntAct=EBI-1348, EBI-706378;
CC       Q9WMX2:- (xeno); NbExp=1; IntAct=EBI-1348, EBI-710918;
CC       P20963:CD247; NbExp=1; IntAct=EBI-1348, EBI-1165705;
CC       Q07666:KHDRBS1; NbExp=3; IntAct=EBI-1348, EBI-1364;
CC       O43561:LAT; NbExp=1; IntAct=EBI-1348, EBI-1222766;
CC       Q9H204:MED28; NbExp=2; IntAct=EBI-1348, EBI-514199;
CC       Q05209:PTPN12; NbExp=1; IntAct=EBI-1348, EBI-2266035;
CC       Q9Y2R2:PTPN22; NbExp=3; IntAct=EBI-1348, EBI-1211241;
CC       P29350:PTPN6; NbExp=1; IntAct=EBI-1348, EBI-78260;
CC       P23467:PTPRB; NbExp=1; IntAct=EBI-1348, EBI-1265766;
CC       P08575:PTPRC; NbExp=1; IntAct=EBI-1348, EBI-1341;
CC       P23470:PTPRG; NbExp=1; IntAct=EBI-1348, EBI-2258115;
CC       Q12913:PTPRJ; NbExp=1; IntAct=EBI-1348, EBI-2264500;
CC       Q15262:PTPRK; NbExp=1; IntAct=EBI-1348, EBI-474052;
CC       P28827:PTPRM; NbExp=1; IntAct=EBI-1348, EBI-2257317;
CC       Q16827:PTPRO; NbExp=1; IntAct=EBI-1348, EBI-723739;
CC       P23471:PTPRZ1; NbExp=1; IntAct=EBI-1348, EBI-2263175;
CC       Q9NP31:SH2D2A; NbExp=1; IntAct=EBI-1348, EBI-490630;
CC       O00401:WASL; NbExp=1; IntAct=EBI-1348, EBI-957615;
CC       P43403:ZAP70; NbExp=1; IntAct=EBI-1348, EBI-1211276;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane; Lipid-anchor;
CC       Cytoplasmic side. Note=Present in lipid rafts in an unactive form.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=Long;
CC         IsoId=P06239-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=P06239-2; Sequence=VSP_005000, VSP_005001;
CC         Note=No experimental confirmation available;
CC       Name=3;
CC         IsoId=P06239-3; Sequence=VSP_016049;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Expressed specifically in lymphoid cells.
CC   -!- DOMAIN: The SH2 domain mediates interaction with SQSTM1.
CC       Interaction is regulated by Ser-59 phosphorylation.
CC   -!- PTM: Phosphorylated on Tyr-394, which increases enzymatic activity
CC       (By similarity). Phosphorylated on Tyr-505, which decreases
CC       activity.
CC   -!- MASS SPECTROMETRY: Mass=57869.42; Method=MALDI; Range=2-509;
CC       Source=PubMed:11840567;
CC   -!- DISEASE: Note=A chromosomal aberration involving LCK is found in
CC       leukemias. Translocation t(1;7)(p34;q34) with TCRB.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. SRC subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SIMILARITY: Contains 1 SH2 domain.
CC   -!- SIMILARITY: Contains 1 SH3 domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAI22320.1; Type=Erroneous initiation; Note=Translation N-terminally extended;
CC       Sequence=CAI22321.1; Type=Erroneous initiation; Note=Translation N-terminally extended;
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/LCKID14ch1p34.html";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Lck entry;
CC       URL="http://en.wikipedia.org/wiki/Lck";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X05027; CAA28691.1; -; mRNA.
DR   EMBL; X13529; CAA31884.1; -; mRNA.
DR   EMBL; M36881; AAA59502.1; -; mRNA.
DR   EMBL; X14055; CAA32211.1; -; Genomic_DNA.
DR   EMBL; X14053; CAA32211.1; JOINED; Genomic_DNA.
DR   EMBL; X14054; CAA32211.1; JOINED; Genomic_DNA.
DR   EMBL; U07236; AAA18225.1; -; mRNA.
DR   EMBL; U23852; AAC50287.1; -; mRNA.
DR   EMBL; BN000073; CAD55807.1; -; Genomic_DNA.
DR   EMBL; AL121991; CAI22320.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AL121991; CAI22321.1; ALT_INIT; Genomic_DNA.
DR   EMBL; CH471059; EAX07543.1; -; Genomic_DNA.
DR   EMBL; BC013200; AAH13200.1; -; mRNA.
DR   EMBL; M21510; AAA59501.1; ALT_TERM; Genomic_DNA.
DR   EMBL; M26692; AAA59503.1; -; Genomic_DNA.
DR   EMBL; AF228313; AAF34794.1; -; mRNA.
DR   EMBL; X06369; CAA29667.1; -; mRNA.
DR   EMBL; X04476; CAA28165.1; -; mRNA.
DR   IPI; IPI00411413; -.
DR   IPI; IPI00515097; -.
DR   IPI; IPI00940423; -.
DR   PIR; JQ0152; OKHULK.
DR   RefSeq; NP_001036236.1; -.
DR   RefSeq; NP_005347.3; -.
DR   UniGene; Hs.470627; -.
DR   PDB; 1BHF; X-ray; 1.80 A; A=119-226.
DR   PDB; 1BHH; X-ray; 1.90 A; A=119-226, B=124-226.
DR   PDB; 1CWD; X-ray; 2.25 A; L=127-222.
DR   PDB; 1CWE; X-ray; 2.30 A; A/C=127-222.
DR   PDB; 1FBZ; X-ray; 2.40 A; A/B=123-226.
DR   PDB; 1H92; NMR; -; A=59-120.
DR   PDB; 1IJR; X-ray; 2.20 A; A=124-226.
DR   PDB; 1KIK; NMR; -; A=64-120.
DR   PDB; 1LCJ; X-ray; 1.80 A; A=119-226.
DR   PDB; 1LCK; X-ray; 2.50 A; A=53-226, B=502-509.
DR   PDB; 1LKK; X-ray; 1.00 A; A=122-226.
DR   PDB; 1LKL; X-ray; 1.80 A; A=123-226.
DR   PDB; 1Q68; NMR; -; B=7-35.
DR   PDB; 1Q69; NMR; -; B=7-35.
DR   PDB; 1QPC; X-ray; 1.60 A; A=231-509.
DR   PDB; 1QPD; X-ray; 2.00 A; A=231-509.
DR   PDB; 1QPE; X-ray; 2.00 A; A=231-509.
DR   PDB; 1QPJ; X-ray; 2.20 A; A=231-509.
DR   PDB; 1X27; X-ray; 2.70 A; A/B/C/D/E/F=64-226.
DR   PDB; 2IIM; X-ray; 1.00 A; A=59-119.
DR   PDB; 2OF2; X-ray; 2.00 A; A=231-501.
DR   PDB; 2OF4; X-ray; 2.70 A; A=231-501.
DR   PDB; 2OFU; X-ray; 2.00 A; A=229-501.
DR   PDB; 2OFV; X-ray; 2.00 A; A/B=226-502.
DR   PDB; 2OG8; X-ray; 2.30 A; A/B=236-500.
DR   PDB; 2PL0; X-ray; 2.80 A; A=225-509.
DR   PDB; 2ZM1; X-ray; 2.10 A; A=225-509.
DR   PDB; 2ZM4; X-ray; 2.70 A; A=225-509.
DR   PDB; 2ZYB; X-ray; 2.55 A; A=225-509.
DR   PDB; 3AC1; X-ray; 1.99 A; A=225-509.
DR   PDB; 3AC2; X-ray; 2.10 A; A=225-509.
DR   PDB; 3AC3; X-ray; 2.55 A; A=225-509.
DR   PDB; 3AC4; X-ray; 2.70 A; A=225-509.
DR   PDB; 3AC5; X-ray; 2.50 A; A=225-509.
DR   PDB; 3AC8; X-ray; 2.30 A; A=225-509.
DR   PDB; 3ACJ; X-ray; 2.20 A; A=225-509.
DR   PDB; 3ACK; X-ray; 2.60 A; A=225-509.
DR   PDB; 3B2W; X-ray; 2.30 A; A=226-502.
DR   PDB; 3BRH; X-ray; 2.20 A; C/D=391-397.
DR   PDB; 3BYM; X-ray; 2.00 A; A=230-501.
DR   PDB; 3BYO; X-ray; 2.00 A; A=231-501.
DR   PDB; 3BYS; X-ray; 2.20 A; A=225-501.
DR   PDB; 3BYU; X-ray; 2.30 A; A=225-501.
DR   PDB; 3KXZ; X-ray; 2.37 A; A=225-509.
DR   PDB; 3LCK; X-ray; 1.70 A; A=231-501.
DR   PDB; 3MPM; X-ray; 1.95 A; A=237-501.
DR   PDBsum; 1BHF; -.
DR   PDBsum; 1BHH; -.
DR   PDBsum; 1CWD; -.
DR   PDBsum; 1CWE; -.
DR   PDBsum; 1FBZ; -.
DR   PDBsum; 1H92; -.
DR   PDBsum; 1IJR; -.
DR   PDBsum; 1KIK; -.
DR   PDBsum; 1LCJ; -.
DR   PDBsum; 1LCK; -.
DR   PDBsum; 1LKK; -.
DR   PDBsum; 1LKL; -.
DR   PDBsum; 1Q68; -.
DR   PDBsum; 1Q69; -.
DR   PDBsum; 1QPC; -.
DR   PDBsum; 1QPD; -.
DR   PDBsum; 1QPE; -.
DR   PDBsum; 1QPJ; -.
DR   PDBsum; 1X27; -.
DR   PDBsum; 2IIM; -.
DR   PDBsum; 2OF2; -.
DR   PDBsum; 2OF4; -.
DR   PDBsum; 2OFU; -.
DR   PDBsum; 2OFV; -.
DR   PDBsum; 2OG8; -.
DR   PDBsum; 2PL0; -.
DR   PDBsum; 2ZM1; -.
DR   PDBsum; 2ZM4; -.
DR   PDBsum; 2ZYB; -.
DR   PDBsum; 3AC1; -.
DR   PDBsum; 3AC2; -.
DR   PDBsum; 3AC3; -.
DR   PDBsum; 3AC4; -.
DR   PDBsum; 3AC5; -.
DR   PDBsum; 3AC8; -.
DR   PDBsum; 3ACJ; -.
DR   PDBsum; 3ACK; -.
DR   PDBsum; 3B2W; -.
DR   PDBsum; 3BRH; -.
DR   PDBsum; 3BYM; -.
DR   PDBsum; 3BYO; -.
DR   PDBsum; 3BYS; -.
DR   PDBsum; 3BYU; -.
DR   PDBsum; 3KXZ; -.
DR   PDBsum; 3LCK; -.
DR   PDBsum; 3MPM; -.
DR   ProteinModelPortal; P06239; -.
DR   SMR; P06239; 65-509.
DR   DIP; DIP-553N; -.
DR   IntAct; P06239; 42.
DR   MINT; MINT-110378; -.
DR   STRING; P06239; -.
DR   PhosphoSite; P06239; -.
DR   PRIDE; P06239; -.
DR   Ensembl; ENST00000336890; ENSP00000337825; ENSG00000182866.
DR   Ensembl; ENST00000398345; ENSP00000381387; ENSG00000182866.
DR   GeneID; 3932; -.
DR   KEGG; hsa:3932; -.
DR   UCSC; uc001bux.1; human.
DR   UCSC; uc001buz.1; human.
DR   CTD; 3932; -.
DR   GeneCards; GC01P032716; -.
DR   HGNC; HGNC:6524; LCK.
DR   HPA; CAB003816; -.
DR   HPA; HPA003494; -.
DR   MIM; 153390; gene.
DR   PharmGKB; PA30307; -.
DR   eggNOG; prNOG11382; -.
DR   HOVERGEN; HBG008761; -.
DR   OMA; RHYTNAS; -.
DR   OrthoDB; EOG9BZQMQ; -.
DR   BRENDA; 2.7.10.2; 247.
DR   Pathway_Interaction_DB; alphasynuclein_pathway; Alpha-synuclein signaling.
DR   Pathway_Interaction_DB; amb2_neutrophils_pathway; amb2 Integrin signaling.
DR   Pathway_Interaction_DB; nfkappabatypicalpathway; Atypical NF-kappaB pathway.
DR   Pathway_Interaction_DB; pi3kcipathway; Class I PI3K signaling events.
DR   Pathway_Interaction_DB; epha_fwdpathway; EPHA forward signaling.
DR   Pathway_Interaction_DB; ephrinbrevpathway; Ephrin B reverse signaling.
DR   Pathway_Interaction_DB; glypican_1pathway; Glypican 1 network.
DR   Pathway_Interaction_DB; il12_2pathway; IL12-mediated signaling events.
DR   Pathway_Interaction_DB; il2_pi3kpathway; IL2 signaling events mediated by PI3K.
DR   Pathway_Interaction_DB; il2_stat5pathway; IL2 signaling events mediated by STAT5.
DR   Pathway_Interaction_DB; il2_1pathway; IL2-mediated signaling events.
DR   Pathway_Interaction_DB; pdgfrbpathway; PDGFR-beta signaling pathway.
DR   Pathway_Interaction_DB; p38alphabetapathway; Regulation of p38-alpha and p38-beta.
DR   Pathway_Interaction_DB; ptp1bpathway; Signaling events mediated by PTP1B.
DR   Pathway_Interaction_DB; tcrpathway; TCR signaling in naive CD4+ T cells.
DR   Pathway_Interaction_DB; cd8tcrpathway; TCR signaling in naive CD8+ T cells.
DR   Pathway_Interaction_DB; txa2pathway; Thromboxane A2 receptor signaling.
DR   Reactome; REACT_604; Hemostasis.
DR   Reactome; REACT_6185; HIV Infection.
DR   Reactome; REACT_6900; Signaling in Immune system.
DR   BindingDB; P06239; -.
DR   DrugBank; DB01254; Dasatinib.
DR   NextBio; 15441; -.
DR   ArrayExpress; P06239; -.
DR   Bgee; P06239; -.
DR   CleanEx; HS_LCK; -.
DR   Genevestigator; P06239; -.
DR   GermOnline; ENSG00000182866; Homo sapiens.
DR   GO; GO:0005829; C:cytosol; EXP:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0000242; C:pericentriolar material; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0051117; F:ATPase binding; IPI:UniProtKB.
DR   GO; GO:0042609; F:CD4 receptor binding; IPI:UniProtKB.
DR   GO; GO:0042610; F:CD8 receptor binding; IPI:UniProtKB.
DR   GO; GO:0001948; F:glycoprotein binding; IPI:UniProtKB.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kina...; IEA:EC.
DR   GO; GO:0043548; F:phosphoinositide 3-kinase binding; IPI:UniProtKB.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004722; F:protein serine/threonine phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0042169; F:SH2 domain binding; IPI:UniProtKB.
DR   GO; GO:0006919; P:activation of caspase activity; IDA:UniProtKB.
DR   GO; GO:0006882; P:cellular zinc ion homeostasis; IEP:UniProtKB.
DR   GO; GO:0006917; P:induction of apoptosis; IMP:UniProtKB.
DR   GO; GO:0044419; P:interspecies interaction between organisms; IEA:UniProtKB-KW.
DR   GO; GO:0050870; P:positive regulation of T cell activation; IDA:UniProtKB.
DR   GO; GO:0050862; P:positive regulation of T cell receptor sign...; NAS:UniProtKB.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; IDA:UniProtKB.
DR   GO; GO:0051209; P:release of sequestered calcium ion into cyt...; ISS:UniProtKB.
DR   GO; GO:0042493; P:response to drug; IDA:UniProtKB.
DR   GO; GO:0030217; P:T cell differentiation; IMP:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR020749; Tyr_kinase_non-rcpt_Lck.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   Gene3D; G3DSA:3.30.505.10; SH2; 1.
DR   PANTHER; PTHR23256:SF260; Tyr_kinase_non-rcpt_Lck; 1.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   SUPFAM; SSF50044; SH3; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Cell membrane; Chromosomal rearrangement; Complete proteome;
KW   Cytoplasm; Disease mutation; Host-virus interaction; Kinase;
KW   Lipoprotein; Membrane; Myristate; Nucleotide-binding; Palmitate;
KW   Phosphoprotein; Polymorphism; Proto-oncogene; SH2 domain; SH3 domain;
KW   Transferase; Tyrosine-protein kinase.
FT   INIT_MET      1      1       Removed (Probable).
FT   CHAIN         2    509       Tyrosine-protein kinase Lck.
FT                                /FTId=PRO_0000088124.
FT   DOMAIN       61    121       SH3.
FT   DOMAIN      127    224       SH2.
FT   DOMAIN      245    498       Protein kinase.
FT   NP_BIND     251    259       ATP (By similarity).
FT   REGION        2     72       Interactions with CD4 and CD8 (By
FT                                similarity).
FT   REGION      154    242       Interaction with PTPRH.
FT   ACT_SITE    364    364       Proton acceptor (By similarity).
FT   BINDING     273    273       ATP (By similarity).
FT   MOD_RES     102    102       Phosphoserine.
FT   MOD_RES     159    159       Phosphothreonine.
FT   MOD_RES     162    162       Phosphoserine.
FT   MOD_RES     179    179       N6-acetyllysine.
FT   MOD_RES     192    192       Phosphotyrosine.
FT   MOD_RES     194    194       Phosphoserine.
FT   MOD_RES     213    213       Phosphoserine.
FT   MOD_RES     394    394       Phosphotyrosine; by autocatalysis.
FT   MOD_RES     501    501       Phosphothreonine.
FT   MOD_RES     505    505       Phosphotyrosine.
FT   LIPID         2      2       N-myristoyl glycine (By similarity).
FT   LIPID         3      3       S-palmitoyl cysteine (By similarity).
FT   LIPID         5      5       S-palmitoyl cysteine (By similarity).
FT   VAR_SEQ     321    321       N -> NDTLLDSQLEEKGLGASPWGNLGQQLLLLPT (in
FT                                isoform 3).
FT                                /FTId=VSP_016049.
FT   VAR_SEQ     348    363       IAEGMAFIEERNYIHR -> VRRLGRGAGQGNRPVT (in
FT                                isoform Short).
FT                                /FTId=VSP_005000.
FT   VAR_SEQ     364    509       Missing (in isoform Short).
FT                                /FTId=VSP_005001.
FT   VARIANT      28     28       V -> L (in leukemia).
FT                                /FTId=VAR_013463.
FT   VARIANT     201    201       G -> S (in dbSNP:rs11567841).
FT                                /FTId=VAR_051697.
FT   VARIANT     232    232       P -> PQKP (in leukemia).
FT                                /FTId=VAR_013464.
FT   VARIANT     353    353       A -> V (in leukemia).
FT                                /FTId=VAR_013465.
FT   VARIANT     447    447       P -> L (in leukemia).
FT                                /FTId=VAR_013466.
FT   MUTAGEN      59     59       S->E: Allows interaction with SQSTM1.
FT   MUTAGEN     154    154       R->K: No effect on interaction with
FT                                SQSTM1.
FT   CONFLICT     29     29       P -> R (in Ref. 2; AAA59502).
FT   CONFLICT     35     35       T -> R (in Ref. 2; AAA59502).
FT   CONFLICT     87     87       Q -> P (in Ref. 2; CAA31884/AAA59502).
FT   CONFLICT    206    211       VRHYTN -> ASAITPI (in Ref. 1; CAA28691).
FT   CONFLICT    254    254       G -> A (in Ref. 2; AAA59502).
FT   CONFLICT    258    267       EVWMGYYNGH -> RCGWGTTTGT (in Ref. 1;
FT                                CAA28691).
FT   CONFLICT    282    286       PDAFL -> AGRLP (in Ref. 1; CAA28691).
FT   CONFLICT    375    375       T -> A (in Ref. 14).
FT   CONFLICT    472    472       L -> H (in Ref. 13).
FT   CONFLICT    504    509       QYQPQP -> STA (in Ref. 1; CAA28691).
FT   HELIX        12     15
FT   STRAND       21     23
FT   TURN         60     63
FT   STRAND       65     70
FT   STRAND       87     92
FT   STRAND       95    102
FT   TURN        103    105
FT   STRAND      108    112
FT   HELIX       113    115
FT   STRAND      116    118
FT   HELIX       134    141
FT   STRAND      151    155
FT   STRAND      157    159
FT   STRAND      163    171
FT   TURN        172    174
FT   STRAND      175    185
FT   STRAND      191    194
FT   STRAND      199    201
FT   HELIX       202    211
FT   STRAND      216    218
FT   TURN        233    235
FT   HELIX       242    244
FT   STRAND      245    254
FT   STRAND      257    264
FT   TURN        265    267
FT   STRAND      268    275
FT   HELIX       282    294
FT   STRAND      303    307
FT   STRAND      309    311
FT   STRAND      313    317
FT   HELIX       324    327
FT   HELIX       331    334
FT   HELIX       338    357
FT   HELIX       367    369
FT   STRAND      370    372
FT   STRAND      378    380
FT   STRAND      390    392
FT   TURN        404    406
FT   HELIX       409    414
FT   HELIX       419    434
FT   TURN        435    437
FT   HELIX       446    454
FT   HELIX       467    476
FT   HELIX       481    483
FT   HELIX       487    500
SQ   SEQUENCE   509 AA;  58001 MW;  44BFF0D43FFB420D CRC64;
     MGCGCSSHPE DDWMENIDVC ENCHYPIVPL DGKGTLLIRN GSEVRDPLVT YEGSNPPASP
     LQDNLVIALH SYEPSHDGDL GFEKGEQLRI LEQSGEWWKA QSLTTGQEGF IPFNFVAKAN
     SLEPEPWFFK NLSRKDAERQ LLAPGNTHGS FLIRESESTA GSFSLSVRDF DQNQGEVVKH
     YKIRNLDNGG FYISPRITFP GLHELVRHYT NASDGLCTRL SRPCQTQKPQ KPWWEDEWEV
     PRETLKLVER LGAGQFGEVW MGYYNGHTKV AVKSLKQGSM SPDAFLAEAN LMKQLQHQRL
     VRLYAVVTQE PIYIITEYME NGSLVDFLKT PSGIKLTINK LLDMAAQIAE GMAFIEERNY
     IHRDLRAANI LVSDTLSCKI ADFGLARLIE DNEYTAREGA KFPIKWTAPE AINYGTFTIK
     SDVWSFGILL TEIVTHGRIP YPGMTNPEVI QNLERGYRMV RPDNCPEELY QLMRLCWKER
     PEDRPTFDYL RSVLEDFFTA TEGQYQPQP
//
